WASHINGTON DC (February 25, 2019) – Jonathan Kimball joins the Association for Accessible Medicines as Vice President, Trade and International Affairs, effective today.
“Jonathan will bring a wealth of government and industry advocacy experience to an area of increasing importance to AAM and our members,” said Jeff Francer, AAM’s Senior Vice President and General Counsel. “We are extremely lucky to have him on our team.”
Kimball previously served as Managing Director, Healthcare Policy, at Burson Cohn & Wolfe (previously Burson-Marsteller), where he worked with pharmaceutical companies, medical device companies and trade associations to develop public affairs and advocacy campaigns in the U.S. and international markets.
From 1998 to 2007, Kimball served as Director for Central and Southeastern Europe and as a Desk Officer for Market Access and Compliance in the International Trade Administration of the U.S. Department of Commerce. At Commerce, Jonathan managed a team working to ensure fair market access for U.S. companies in 16 countries. Subsequently, he served as Deputy Vice President, International, at PhRMA, where he led the association’s Europe, Middle East, Africa and the Americas’ government advocacy. At PhRMA he managed staff in the association’s offices in Washington, Brussels, Dubai and Amman.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.